普洛药业(000739) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was ¥7,879,672,743.47, representing a 9.28% increase from ¥7,210,711,386.14 in 2019[10] - The net profit attributable to shareholders for 2020 was ¥816,730,067.12, a 47.58% increase compared to ¥553,400,761.42 in 2019[10] - The basic earnings per share for 2020 was ¥0.6930, up 47.57% from ¥0.4696 in 2019[10] - The total operating revenue for 2020 was approximately ¥7.88 billion, representing a year-on-year increase of 9.28% from ¥7.21 billion in 2019[30] - The pharmaceutical main business revenue was approximately ¥7.85 billion, accounting for 99.64% of total revenue, with a year-on-year increase of 9.08%[30] - The total operating profit for 2020 was approximately ¥969.71 million, an increase of 50.6% compared to ¥644.15 million in 2019[162] - The comprehensive income total for 2020 was approximately ¥817.14 million, compared to ¥553.34 million in 2019, reflecting a significant growth[163] - The total profit for 2020 was approximately ¥961.15 million, an increase of 51.6% compared to ¥633.73 million in 2019[162] Assets and Liabilities - The total assets at the end of 2020 were ¥7,494,787,957.34, reflecting a 14.91% increase from ¥6,522,585,923.42 at the end of 2019[10] - The total liabilities of Pro Pharmaceutical Co., Ltd. increased to CNY 3,104,112,724.02 from CNY 2,754,599,136.14, marking a rise of around 12.7%[155] - The company's equity attributable to shareholders rose to CNY 4,390,675,233.32, compared to CNY 3,767,986,787.28 in 2019, reflecting an increase of approximately 16.5%[156] - The total current liabilities increased to CNY 2,896,461,565.37 from CNY 2,561,555,217.89, reflecting a growth of approximately 13.1%[155] Cash Flow - The net cash flow from operating activities for 2020 was ¥1,059,526,132.55, a decrease of 22.10% from ¥1,360,066,190.36 in 2019[10] - The company reported a net increase in cash and cash equivalents of CNY 1,206,365,433.90, compared to CNY 216,352,891.90 in 2019, indicating a substantial improvement[169] - The total cash and cash equivalents at the end of 2020 reached CNY 1,924,438,773.93, up from CNY 718,073,340.03 at the end of 2019[169] Research and Development - The company expanded its R&D team by hiring 89 new technical personnel, including 35 with doctoral or master's degrees, with total R&D investment reaching 355 million CNY, accounting for 4.51% of operating revenue[25] - The company plans to focus on research and development in biopharmaceutical technology and expand its market presence through strategic investments[192] - The company has established five career development paths, including management and research sequences, with corresponding assessment and incentive mechanisms[119] Market Position and Strategy - The company has established a strong market position in the pharmaceutical manufacturing industry, focusing on APIs, CDMO services, and formulation business[16] - The company has a global sales network covering over 70 countries and regions, with a significant export position in chemical APIs[21] - The company plans to continue focusing on its development strategy of refining raw materials, strengthening CDMO, and optimizing formulations, while enhancing R&D innovation and operational efficiency[50] Compliance and Governance - The company has maintained compliance with its commitments regarding independence and avoidance of competition, as stated in its long-term commitments[57] - There were no significant accounting errors or restatements during the reporting period, ensuring the integrity of the financial statements[59] - The company has engaged an independent auditor to assess the effectiveness of its internal controls, ensuring compliance with regulatory standards[123] Environmental Responsibility - The company invested approximately 81.88 million CNY in 2020 to enhance wastewater treatment capabilities and reduce total water pollutant emissions[89] - The company has implemented various pollution control measures, ensuring emissions are within regulatory limits[87] - The company is actively engaged in comprehensive air pollution control efforts as per national guidelines, focusing on volatile organic compounds[92] Shareholder Information - The company plans to distribute a cash dividend of ¥2.43 per 10 shares based on a total share capital of 1,178,523,492 shares as of December 31, 2020[2] - The company reported a cash dividend of ¥286,381,208.56 for the year 2020, which is 35.06% of the net profit attributable to ordinary shareholders[54] - The total distributable profit for the period was 300,416,376.58 CNY, indicating a strong commitment to returning value to shareholders[56] Employee and Management Changes - The company appointed Xu Xinliang as General Manager and Jin Min as Senior Vice President on January 2, 2020[109] - The company reported a significant management change with the dismissal of Zhu Fangmeng as General Manager due to work reasons on January 2, 2020[109] - The company has a diverse management team with members holding advanced degrees and extensive experience in various sectors, including pharmaceuticals and finance[110]